CY2027 MA Bids Lock In as Actuaries Navigate Tighter Margins

The June 1, 2026 deadline closed the CY2027 Medicare Advantage bid cycle. The April 6 final rate announcement had set a 2.48% net average payment increase, roughly $13 billion more than CY2026, reaching 4.98% once risk score trend is included.

Underneath the headline the picture is tighter. Wakely estimates that under simplifying assumptions, risk-adjusted bid revenue is down roughly 0.35%, which is the number bid models actually had to work against.

Key Takeaways

• A 239 basis point swing separated the April final notice from January's advance notice of 0.09%, driven mostly by CMS retaining the existing V28 calibration, worth roughly 220 basis points on its own.
• $2 PMPM is the net gain in supplemental benefit budget in a worked bid for a 50,000-member HMO, about $1.2 million a year, after medical trend and the chart review exclusion.
• 1.53% of total payments is the aggregate hit from excluding unlinked chart review diagnoses, down from 1.78% proposed. Plan-level impacts run below 0.5% for encounter-coded plans and above 3% for chart-review-dependent ones.
• $18.6 billion over the next decade flows to MA insurers from the Star Ratings restructuring, which removed 11 administrative measures and put roughly 65% of scoring weight on clinical outcomes and patient experience.
• A 3.32% reduction is what Georgetown estimated the deferred V28 recalibration would have cost. Deferring it does not remove it.

Decomposing the 2.48%

The April number is a 239 basis point positive swing from the January advance notice, which had projected 0.09%. Three components account for nearly all of it.

CMS retaining the existing V28 risk adjustment model calibration contributed roughly 220 basis points. The softened chart review exclusion, via a new switching exception, added 25 basis points. Updated Part A and Part B per-capita spending data added 36.

Translating that into plan revenue meant decomposing by county, plan type and population mix, because the 5.33% effective growth rate is a national average over a wide distribution. Counties with above-average fee-for-service cost growth, particularly those carrying strong inpatient utilization from the 2025 and 2026 respiratory season and elevated Part B oncology and metabolic drug spend, drew proportionally larger benchmark increases. Rural markets where FFS growth has lagged came in 100 to 200 basis points below the national rate.

The rework was real. For a plan with 100,000 members at a $1,200 monthly benchmark, the move off the advance notice baseline added roughly $34 million in annual revenue against January projections, with eight weeks between the rate announcement and the bid deadline to redeploy it.

Where the Increase Actually Lands

The gap between a favorable headline and a constrained bid is visible in a component walk. Take a broad-market HMO with 50,000 members in a county at a $1,100 monthly benchmark and a 5% quality bonus.

The benchmark rises 5.0% and the rebate rises 9.9%, but the plan's own bid rises 4.4% on medical trend and the chart review exclusion takes an estimated $8 PMPM back out. Net supplemental benefit budget improves $2 PMPM, about $1.2 million a year at this membership. That funds a modest over-the-counter allowance or moves dental from preventive to comprehensive. It does not fund a package.

The chart review line is where plan-level results diverge from the aggregate. CMS put the exclusion at 1.53% of total payments after the switching exception, down from 1.78% proposed, but the distribution around that average is skewed. Plans whose diagnoses flow through routine encounters and specialist claims may land below 0.5%. Plans built on retrospective review and in-home assessments face 3% or more, which is the shape of the $7 billion aggregate impact.

The larger lever is the star rating. A plan at 4.0 stars receives a 5% benchmark bonus and a plan at 3.5 receives nothing, so that threshold is worth more than the entire base rate increase. The restructuring removed 11 administrative measures and moved roughly 65% of scoring weight to clinical outcomes and patient experience, with Axene Health Partners estimating the share of plans qualifying for bonus payments could rise 8 to 12 percentage points and $18.6 billion flowing to insurers over the decade.

Clinical infrastructure takes 18 to 24 months to move a HEDIS measure, so that redistribution was largely settled before the CY2027 bid spreadsheet opened.

The Deferral Moves the Problem Rather Than Solving It

The single most valuable decision for CY2027 bids was CMS declining to recalibrate V28. Georgetown estimated that replacing the 2018 and 2019 base with 2023 and 2024 data would have cut aggregate payments roughly 3.32%.

Plans therefore continue pricing on calibration data that predates the pandemic, the GLP-1 expansion and several structural shifts in Medicare spending. The divergence between that base and current experience does not stop accumulating because the recalibration was deferred. When CMS finalizes it, likely in the CY2028 or CY2029 cycle, the adjustment is larger for the delay, which is why prudent three-year projections carried a scenario in the 3.5% to 4.5% range rather than 3.32%.

That converts the CY2027 increase into a timing question rather than a windfall. A plan that spent it on benefit enrichment and a plan that reserved part of it against recalibration bid the same rate environment into different balance sheets.

Two other lags compound it. The chart review revenue reduction is immediate and quantifiable, while the recovery from converting to prospective encounter-based coding accrues over 12 to 18 months as providers change workflows and EHR templates, so CY2027 absorbs a compression that cannot be offset within the contract year.

And Part D year-one experience came in above plan. Catastrophic phase utilization ran roughly 22% above the base cases used for CY2026 bids, concentrated in GLP-1 agonists, oncology biologics and autoimmune therapies where lower cost-sharing pulled utilization earlier in the benefit year. CY2026 absorbed part of that through risk corridor recoveries. CY2027 prices the observed trajectory without the same cushion, and the GLP-1 Bridge program's $50 monthly copay outside the Part D structure adds a take-up assumption nobody has data for.